Loading stock data…
TRAW
$1.49+0.06 (+4.20%)
Pre-Market$1.61+0.12 (+8.05%)· Last close May 1
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Traws Pharma, Inc. in the Healthcare sector is trading at $1.49. The stock is currently 54% below its 52-week high of $3.27, remaining 20.7% below its 200-day moving average. Technical signals show neutral RSI of 45 and bullish MACD crossover, explaining why TRAW maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.49
Potential Downside
4009.3%
Whystock Fair Value$-58.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are d...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.39M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
1.49
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-380.81%
Volume
Today's trading volume
209,211
Recent News
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Traws Pharma, Inc. Q4 2025 Earnings Call Summary
Moby summary of Traws Pharma, Inc.'s Q4 2025 earnings call
Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...
Traws Pharma Inc (TRAW) reports a remarkable financial turnaround in 2025, driven by strategic financing and promising developments in its flu program.
hVIVO, Connecting Excellence, ACG Metals, Kodal Minerals, Ariana Resources, Sunda Energy
hVIVO PLC (AIM:HVO) has signed a deal with Traws Pharma to run an influenza human challenge trial in London. The contract coincides with a rebrand, bringing all its services under one roof. Connecting Excellence Group PLC (AQSE:XCE, OTCQB:XCELF) has been paid in Bitcoin for recruitment services, a first for a UK-listed recruiter. The payment of 0.516 BTC takes its total treasury holdings to just under 53 Bitcoin. ACG Metals Ltd (LSE:ACG, OTC:ACGAF) posted adjusted EBITDA of $76.3 million for 2025, with its Gediktepe mine in Turkey delivering strong margins. A transition to copper and zinc concentrate production is on track for mid-2026. Kodal Minerals (AIM:KOD) had a record month in March at its Bougouni Lithium Project in Mali, topping 10,900 tonnes of spodumene concentrate. A third export shipment departed on 12 April, taking cumulative exports to around 69,000 tonnes. Ariana Resources PLC (AIM:AAU, ASX:AA2, FRA:4A6) has appointed Michael Atkins as its new chair, as the company begins a broader transformation around its Dokwe Gold Project in Zimbabwe. Sunda Energy PLC (AIM:SNDA) has paid a $1.5 million deposit on its proposed New Zealand acquisition and filed for regulatory approval. The deal moves it a step closer to adding new energy assets in the region. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.